SMTL ID : 3oom.1

Crystal structure of the ACVR1 kinase domain in complex with the imidazo[1,2-b]pyridazine inhibitor K00507

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.00 Å

Oligo State

homo-dimer

Ligands

4 x PO4: PHOSPHATE ION(Non-functional Binders)

PO4.1: 5 residues within 4Å: Chain A: R.182, N.239, D.240, P.241 Ligands: EDO.4 5 PLIP interactions: 5 interactions with chain A Hydrogen bonds: A:D.240, A:D.240 Water bridges: A:R.182, A:N.239 Salt bridges: A:R.182 PO4.2: 3 residues within 4Å: Chain A: H.88, K.147, K.148 5 PLIP interactions: 5 interactions with chain A Hydrogen bonds: A:K.148 Water bridges: A:E.89, A:N.149 Salt bridges: A:H.88, A:K.148 PO4.19: 5 residues within 4Å: Chain B: R.182, N.239, D.240, P.241 Ligands: EDO.22 4 PLIP interactions: 4 interactions with chain B Hydrogen bonds: B:D.240 Water bridges: B:R.182, B:N.239 Salt bridges: B:R.182 PO4.20: 3 residues within 4Å: Chain B: H.88, K.147, K.148 5 PLIP interactions: 5 interactions with chain B Hydrogen bonds: B:K.148 Water bridges: B:E.89, B:N.149 Salt bridges: B:H.88, B:K.148

2 x 507: 1-{3-[6-(tetrahydro-2H-pyran-4-ylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl}ethanone(Non-covalent)

507.3: 16 residues within 4Å: Chain A: V.16, G.17, Y.21, V.24, A.35, L.65, T.85, H.86, Y.87, H.88, G.91, K.142, N.143, L.145, A.155, D.156 9 PLIP interactions: 9 interactions with chain A Hydrophobic interactions: A:V.16, A:A.35, A:L.65, A:Y.87, A:L.145, A:A.155 Hydrogen bonds: A:H.88 Water bridges: A:V.16, A:K.37 507.21: 16 residues within 4Å: Chain B: V.16, G.17, Y.21, V.24, A.35, L.65, T.85, H.86, Y.87, H.88, G.91, K.142, N.143, L.145, A.155, D.156 9 PLIP interactions: 9 interactions with chain B Hydrophobic interactions: B:V.16, B:A.35, B:L.65, B:Y.87, B:L.145, B:A.155 Hydrogen bonds: B:H.88 Water bridges: B:V.16, B:K.37

30 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)

EDO.4: 3 residues within 4Å: Chain A: K.140, T.180 Ligands: PO4.1 Ligand excluded by PLIP EDO.5: 5 residues within 4Å: Chain A: H.61, H.120, I.123, K.294 Ligands: EDO.18 Ligand excluded by PLIP EDO.6: 8 residues within 4Å: Chain A: H.61, E.62, I.64, L.65, G.66, H.86, H.88, C.153 Ligand excluded by PLIP EDO.7: 5 residues within 4Å: Chain A: R.182, Y.234, V.237, P.238, N.239 Ligand excluded by PLIP EDO.8: 4 residues within 4Å: Chain A: R.203, P.284, S.285, R.287 Ligand excluded by PLIP EDO.9: 7 residues within 4Å: Chain A: E.44, K.45, F.48 Chain B: E.44, K.45, F.48 Ligands: EDO.27 Ligand excluded by PLIP EDO.10: 5 residues within 4Å: Chain A: S.41, E.44, T.79, L.81 Chain B: F.48 Ligand excluded by PLIP EDO.11: 1 residues within 4Å: Chain A: H.76 Ligand excluded by PLIP EDO.12: 4 residues within 4Å: Chain A: K.45 Chain B: K.45, N.174 Ligands: EDO.30 Ligand excluded by PLIP EDO.13: 6 residues within 4Å: Chain A: P.132, M.162, H.163, S.164, Q.169, D.171 Ligand excluded by PLIP EDO.14: 1 residues within 4Å: Chain A: C.197 Ligand excluded by PLIP EDO.15: 4 residues within 4Å: Chain A: Y.94, Q.98, Y.229, P.231 Ligand excluded by PLIP EDO.16: 5 residues within 4Å: Chain A: I.123, K.202, T.289, A.290, L.291 Ligand excluded by PLIP EDO.17: 7 residues within 4Å: Chain A: S.70, D.71, M.72 Chain B: T.51, N.55, S.70 Ligands: EDO.35 Ligand excluded by PLIP EDO.18: 5 residues within 4Å: Chain A: H.61, N.63, S.116, K.294 Ligands: EDO.5 Ligand excluded by PLIP EDO.22: 3 residues within 4Å: Chain B: K.140, T.180 Ligands: PO4.19 Ligand excluded by PLIP EDO.23: 5 residues within 4Å: Chain B: H.61, H.120, I.123, K.294 Ligands: EDO.36 Ligand excluded by PLIP EDO.24: 8 residues within 4Å: Chain B: H.61, E.62, I.64, L.65, G.66, H.86, H.88, C.153 Ligand excluded by PLIP EDO.25: 5 residues within 4Å: Chain B: R.182, Y.234, V.237, P.238, N.239 Ligand excluded by PLIP EDO.26: 4 residues within 4Å: Chain B: R.203, P.284, S.285, R.287 Ligand excluded by PLIP EDO.27: 7 residues within 4Å: Chain A: E.44, K.45, F.48 Chain B: E.44, K.45, F.48 Ligands: EDO.9 Ligand excluded by PLIP EDO.28: 5 residues within 4Å: Chain A: F.48 Chain B: S.41, E.44, T.79, L.81 Ligand excluded by PLIP EDO.29: 1 residues within 4Å: Chain B: H.76 Ligand excluded by PLIP EDO.30: 4 residues within 4Å: Chain A: K.45, N.174 Chain B: K.45 Ligands: EDO.12 Ligand excluded by PLIP EDO.31: 6 residues within 4Å: Chain B: P.132, M.162, H.163, S.164, Q.169, D.171 Ligand excluded by PLIP EDO.32: 1 residues within 4Å: Chain B: C.197 Ligand excluded by PLIP EDO.33: 4 residues within 4Å: Chain B: Y.94, Q.98, Y.229, P.231 Ligand excluded by PLIP EDO.34: 5 residues within 4Å: Chain B: I.123, K.202, T.289, A.290, L.291 Ligand excluded by PLIP EDO.35: 7 residues within 4Å: Chain A: T.51, N.55, S.70 Chain B: S.70, D.71, M.72 Ligands: EDO.17 Ligand excluded by PLIP EDO.36: 5 residues within 4Å: Chain B: H.61, N.63, S.116, K.294 Ligands: EDO.23 Ligand excluded by PLIP

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Chaikuad, A. et al., Crystal structure of the ACVR1 kinase domain in complex with the imidazo[1,2-b]pyridazine inhibitor K00507. To be Published

Release Date

2010-10-13

Peptides

Activin receptor type-1: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
A

Activin receptor type-1

Related Entries With Identical Sequence